image: Figure 6. Mexican family carrying the truncated mutant pR552*. (A) Pedigree Analysis: The family pedigree indicates that the father and all three sons present the disease. (B) Data from the family members RBTR4, carried the stop codon retinoblastoma mutation pR552*. (C) Sequence Alignments: A portion of the 17-exon sequence of the family demonstrates the change 1654 C>T, resulting in an anticipated stop codon instead of the normal Arginine (R). (D) The electropherogram of the sequence of a segment of the 17-exon region of the family reveals the mutation 1654 C>T.
Credit: Copyright: © 2025 Peña-Balderas et al.
“In other words, the pR552* mutant behaves more like a gain-of-function or oncogenic mutant. Indeed, a family carrying this mutation showed complete penetrance and high expressivity.”
BUFFALO, NY- January 29, 2025 – A new research paper was published in Volume 16 of Genes & Cancer on January 20, 2025, entitled, “Analysis of pathogenic variants in retinoblastoma reveals a potential gain of function mutation.”
Researchers from Instituto de Física Universidad Autónoma de San Luis Potosí and Hospital Central “Ignacio Morones Prieto” have found a new way a gene mutation might contribute to retinoblastoma, a type of eye cancer that affects young children. The study suggests that a specific genetic change, pR552*, may not only stop the gene from working properly but could also give it a new function that leads to cancer growth. This challenges the common belief that both copies of the retinoblastoma gene (RB1) must be damaged for cancer to develop.
Retinoblastoma is the most common eye cancer in children under five years old. It happens when RB1, which usually helps control cell growth, stops functioning correctly. When this happens, cells can grow uncontrollably and form tumors in the eye. Early signs include the appearance of a white glow in the pupil, misaligned eyes, or vision problems, and prompt detection and treatment can significantly improve outcomes for children.
In this study, the scientists, using in vitro human cell models, examined three specific changes in the RB1 gene. They found that one of them, pR552*, made cells grow, survive, and move more than usual. Unlike other mutations, this one seemed to have an additional harmful effect, even when only one copy of the gene was affected.
The researchers also studied a family in Mexico where the pR552* mutation was passed down from the father to all three of his children, each of whom developed retinoblastoma. This suggests that the mutation might be more powerful than previously thought, possibly causing cancer even if the second copy of the gene is normal.
This discovery could change the way clinicians understand and treat retinoblastoma. Until now, it was believed that both copies of the RB1 gene needed to be damaged for the disease to appear. But this study suggests that just one faulty copy of the gene might be enough to start the disease. If confirmed, these findings could support the development of genetic screening tools to identify at-risk children earlier and inform personalized treatment strategies.
“This mutant pR552* has been identified with high recurrence in different studies in Vietnamese, Portuguese, Canadian, American, English, and Mexican (this work) patients among others; consequently, we decided to continue studying this particular mutant.”
The researchers plan to continue studying this mutation to better understand how it works and whether it also plays a role in other cancers, such as bone and brain tumors. Their work could lead to new approaches for fighting retinoblastoma and possibly other cancers linked to the RB1 gene.
Continue reading: DOI: https://doi.org/10.18632/genesandcancer.239
Correspondence to: Vanesa Olivares-Illana - vanesa@ifisica.uaslp.mx, and Jesús Hernández-Monge - jesus_hernandez_m@hotmail.com
Keywords: cancer, retinoblastoma, gain of function, mutants, pathogenic variants
Click here to sign up for free Altmetric alerts about this article.
About Genes & Cancer:
Genes & Cancer covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that directly relate to these areas of research, Genes & Cancer also aims to attract papers in the areas of genomics, drug development and systems biology.
To learn more about Genes & Cancer, visit www.genesandcancer.com and connect with us on social media:
For media inquiries, please contact media@impactjournals.com.
Genes & Cancer Journal Office
6666 East Quaker St., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 3)
Journal
Genes & Cancer
Method of Research
News article
Subject of Research
Not applicable
Article Title
Analysis of pathogenic variants in retinoblastoma reveals a potential gain of function mutation
Article Publication Date
20-Jan-2025
COI Statement
Authors have no conflicts of interest to declare.